,i #aadth ,,congress #ast ,session ,h4 ,r4 #bccg ,,in ,,the ,,house ,,of ,,representatives ,may #ad1 #bjae ,mr4 ,pitts introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to amend the ,federal ,food1 ,drug1 and ,cosmetic ,act to authorize priority review for breakthrough devices4 #a4 ,priority review for breakthrough devices 7a7 ,in general ,chapter ,v of the ,federal ,food1 ,drug1 and ,cosmetic ,act is amended-- 7#a7 in section #eae7;d7-- 7,a7 by striking paragraph 7#e72 and 7,b7 by redesignating paragraph 7#f7 as paragraph 7#e72 and 7#b7 by inserting after section #eae;,a 7#ba ,u4,s4,c4 #cfj;e-#a7 the following3 #eae;,b4 ,priority review for breakthrough devices 7a7 ,in general ,in order to provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human diseases or conditions1 the ,secretary shall establish a program to provide priority review for devices-- 7#a7 representing breakthrough technologies2 7#b7 for which no approved alternatives exist2 7#c7 offering significant advantages over existing approved or cleared alternatives1 including the potential to1 compared to existing approved or cleared alternatives1 reduce or eliminate the need for hospitalization1 improve patient quality of life1 facilitate patients' ability to manage their own care 7such as through self-directed personal assistance71 or establish long-term clinical efficiencies2 or 7#d7 the availability of which is in the best interest of patients4 7b7 ,request for designation ,a sponsor of a device may request that the ,secretary designate the device for priority review under this section4 ,any such request for designation may be made at any time prior to the submission of an application under section #eae7;c71 a petition for classification under section #eac7;f77#b71 or a notification under section #eaj7k74 7c7 ,designation process 7#a7 ,in general ,not later than #fj calendar days after the receipt of a request under subsection 7b71 the ,secretary shall determine whether the device that is the subject of the request meets the criteria described in subsection 7a74 ,if the ,secretary determines that the device meets the criteria1 the ,secretary shall designate the device for priority review4 7#b7 ,review ,review of a request under subsection 7b7 shall be undertaken by a team that is composed of experienced staff and managers of the ,food and ,drug ,administration and is chaired by a senior manager4 7#c7 ,designation determination ,a determination approving or denying a request under subsection 7b7 shall be considered a significant decision under section #eag;,a and the ,secretary shall provide a written1 substantive summary of the basis for the determination in accordance with section #eag;,a7a74 7#d7 ,reconsideration 7,a7 ,request for reconsideration ,any person whose request under subsection 7b7 is denied may1 within #cj days of the denial1 request reconsideration of the denial in accordance with section #eag;,a7b7-- 7i7 based upon the submission of documents by such person2 or 7ii7 based upon such documents and a meeting or teleconference4 7,b7 ,response ,reconsideration of a designation determination under this paragraph shall be conducted in accordance with section #eag;,a7b74 7#e7 ,withdrawal ,if the ,secretary approves a priority review designation for a device under this section1 the ,secretary may not withdraw the designation based on the fact that the criteria specified in subsection 7a7 are no longer met because of the subsequent clearance or approval of another device that was designated under-- 7,a7 this section2 or 7,b7 section #eae7;d77#e7 7as in effect immediately prior to the enactment of the #bast ,century ,cures ,act74 7d7 ,priority review 7#a7 ,actions ,for purposes of expediting the development and review of devices designated under subsection 7c71 the ,secretary shall-- 7,a7 assign a team of staff1 including a team leader with appropriate subject matter expertise and experience1 for each device for which a request is submitted under subsection 7b72 7,b7 provide for oversight of the team by senior agency personnel to facilitate the efficient development of the device and the efficient review of any submission described in subsection 7b7 for the device2 7,c7 adopt an efficient process for timely dispute resolution2 7,d7 provide for interactive communication with the sponsor of the device during the review process2 7,e7 expedite the ,secretary's review of manufacturing and quality systems compliance1 as applicable2 7,f7 disclose to the sponsor in advance the topics of any consultation concerning the sponsor's device that the ,secretary intends to undertake with external experts or an advisory committee and provide the sponsor an opportunity to recommend such external experts2 7,g7 for applications submitted under section #eae7;c71 provide for advisory committee input1 as the ,secretary determines appropriate 7including in response to the request of the sponsor72 and 7,h7 assign staff to be available within a reasonable time to address questions by institutional review committees concerning the conditions and clinical testing requirements applicable to the investigational use of the device pursuant to an exemption under section #ebj7;g74 7#b7 ,additional actions ,in addition to the actions described in paragraph 7#a71 for purposes of expediting the development and review of devices designated under subsection 7c71 the ,secretary1 in collaboration with the device sponsor1 may1 as appropriate-- 7,a7 coordinate with the sponsor regarding early agreement on a data development plan2 7,b7 take steps to ensure that the design of clinical trials is as efficient as practicable1 such as through adoption of shorter or smaller clinical trials1 application of surrogate endpoints1 and use of adaptive trial designs and ,bayesian statistics1 to the extent scientifically appropriate2 7,c7 facilitate1 to the extent scientifically appropriate1 expedited and efficient development and review of the device through utilization of timely postmarket data collection1 with regard to applications for approval under section #eae7;c72 and 7,d7 agree to clinical protocols that the ,secretary will consider binding on the ,secretary and the sponsor1 subject to-- 7i7 changes agreed to by the sponsor and the ,secretary2 7ii7 changes that the ,secretary determines are required to prevent an unreasonable risk to the public health2 or 7iii7 the identification of a substantial scientific issue determined by the ,secretary to be essential to the safety or effectiveness of the device involved4 7e7 ,priority review guidance 7#a7 ,content ,the ,secretary shall issue guidance on the implementation of this section4 ,such guidance shall include the following3 7,a7 ,the process for a person to seek a priority review designation4 7,b7 ,a template for requests under subsection 7b74 7,c7 ,the criteria the ,secretary will use in evaluating a request for priority review4 7,d7 ,the standards the ,secretary will use in assigning a team of staff1 including team leaders1 to review devices designated for priority review1 including any training required for such personnel on effective and efficient review4 7#b7 ,process ,prior to finalizing the guidance under paragraph 7#a71 the ,secretary shall propose such guidance for public comment4 7f7 ,construction 7#a7 ,purpose ,this section is intended to encourage the ,secretary and provide the ,secretary sufficient authorities to apply efficient and flexible approaches to expedite the development of1 and prioritize the agency's review of1 devices that represent breakthrough technologies4 7#b7 ,construction ,nothing in this section shall be construed to alter the criteria and standards for evaluating an application pursuant to section #eae7;c71 a report and request for classification under section #eac7;f77#b71 or a report under section #eaj7k71 including the recognition of valid scientific evidence as described in section #eac7;a77#c77;,b71 and consideration of the least burdensome means of evaluating device effectiveness or demonstrating substantial equivalence between devices with differing technological characteristics1 as applicable4 ,nothing in this section alters the authority of the ,secretary to act on an application pursuant to section #eae7;d7 before completion of an establishment inspection1 as the ,secretary deems appropriate4 4 7b7 ,conforming amendment related to designation determinations ,section #eag;,a7a77#a7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;g-#a7;a77#a77 is amended by inserting a request for designation under section #eae;,b1 after an application under section #eae14